Image of a hospital dispensary depicting NHS England's new breast cancer treatment

Hundreds of thousands could benefit from preventive breast cancer drug, NHS says

Nearly 300,000 women could be set to benefit from a new preventive breast cancer treatment option, after licensing was granted by the Medicines and Healthcare products Regulatory Agency (MHRA).

The drug known as anastrozole has been used to treat breast cancer previously, but only ‘off-label’ as a preventive intervention – i.e., it was prescribed outside the terms of its license as it was judged by the prescriber to be in the best interests of the patient.

With uptake of the preventive treatment remaining low with the lack of licensing – despite NICE guidance in 2017 recommending that route – this announcement will now see around 289,000 post-menopausal women at a moderate or increased risk of the disease eligible.

Anastrozole is the first drug to be remodelled through NHS England’s innovative Medicines Repurposing Programme which was launched in 2021 after the successes of tocilizumab and dexamethasone as Covid-19 treatments.

Clinical trials show the drug can reduce incidence of breast cancer in its target group by almost 50%.

While some of the women eligible will not opt for anastrozole, it has been calculated that, if 25% do take up the treatment, approximately 2,000 cases of breast cancer could be averted in England, ultimately saving the NHS around £15m.

Nearly 50,000 people are diagnosed with the disease in England every year, making it the most common cancer in the country.

The chief executive of the charity Breast Cancer Now, Baroness Delyth Morgan, said: “The extension of anastrozole’s licence to cover it being used as a risk-reducing treatment is a major step forward that will enable more eligible women with a significant family history of breast cancer, to reduce their chance of developing the disease.”

Anastrozole, which is taken via tablet once a day for five years, is known as an aromatase inhibitor – in other words, it cuts down on the amount of hormone oestrogen produced in the body by blocking an enzyme called aromatase.

MHRA’s chief executive, Dame June Raine, commented: “The MHRA welcomes applications for repurposed medicines and encourages early dialogue from companies or developers considering this.”

After being selected through an open competitive process, licensing for anastrozole was undertaken by Accord Healthcare on a not-for-profit basis.

Image credit: iStock

NHE Nov/Dec 2023

NHE Nov/Dec 2023

AI is key in helping dementia patients live independently for longer.

The Nov/Dec 2023 edition of NHE brings you expert comment and analysis on a range of key health sector topics, from digital transformation to navigating post-pandemic challenges.

Videos...

View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Events

NHE has created a full calendar of events to address the most important issues that influence the delivery of healthcare services. Over 365 days you'll have the opportunity to hear from a range of highly motivating, informative and inspirational speakers. These speakers will equip you with the knowledge and unique insight to enable you to overcome the challenges that you face.

National Health Executive Podcast

Ep 39.
What makes a good NHS manager? with Anthony Painter, Director of Policy at Chartered Management Institute (CMI)

In episode 39 of the National Health Executive podcast, we were joined by Anthony Painter, who is the director of policy at the Chartered Management Institute (CMI), to discuss all things management within the UK health sector and NHS.
 

During the podcast, Anthony shared some of the recent research CMI conducted in partnership with the Social Market Foundation, which centred around the state of management and leadership within the NHS.

More articles...

View all